EffRx Pharmaceuticals SA is a commercial-stage pharmaceutical company, based in Switzerland, that develops and commercializes prescription medications for specialty indications. The primary focus is on therapeutics for men and women with musculoskeletal, genitourinary and endocrine disorders. The business model is centred around providing superior clinical and commercial value propositions for physicians, payers and patients. We address real, unmet medical needs and strive to improve patient outcomes.
Our lead commercialized product, Binosto® for the treatment of osteoporosis is marketed in the US, Europe, selected MENA and Asian countries. Binosto® offers a number of potential advantages over traditional therapeutic approaches, and its successful approval and commercial launch was an important milestone for EffRx.
EffRx has set up a global network of partners to commercialize and distribute its products. These respected companies have a strong local footprint and an established sales force in the relevant therapeutic areas.
In 2014, EffRx also received an orphan drug designation (ODD) from the FDA for a pipeline compound. EffRx has an experienced Board of Directors and Management Team with proven development and commercialization success within pharmaceutical and biotechnology companies.